Exabis Library
Welcome to the e-CCO Library!
P424 Economic evaluation of vedolizumab SC for the treatment of moderate-to-severe ulcerative colitis in Canada
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P424: Association between infliximab trough levels, clinical remission, mucosal healing and quality of life in patients with inflammatory bowel disease on maintenance therapy
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P424: Do antiTNF through levels correlate with joint extraintestinal manifestations (EIM) activity in Inflammatory bowel disease (IBD) patients?
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P424: Is the switch to a second thiopurine a safe strategy in elderly patients with inflammatory bowel disease? A multi-centre cohort study of the ENEIDA registry
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P424: Monitoring response to adalimumab therapy in Crohn’s disease patients by bowel ultrasound: Sub-analysis from TRUST
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P424: Surgery for children with Crohn’s disease.
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P424: Treatment persistence of first-line anti-TNF therapy in patients with inflammatory bowel diseases: results from a real-world study over 20 years
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P424: Uptake of a switching program for patients receiving intravenous infliximab and vedolizumab to subcutaneous preparations
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P425 SPOSIB SB2: a Sicilian prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar SB2
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P425: Biosimilar infliximab in real-life Crohn's disease treatment in anti-TNF-alpha naïve and non-naïve patients in comparison to biologic originator: a comparative observational cohort study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P425: Comparison of therapeutic choices in biologic experienced Crohn’s disease and ulcerative colitis patients in Europe: discontinuation rates because of disease improvements
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P425: Development of an enzyme-linked immunosorbent assay for therapeutic drug monitoring of ustekinumab
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P425: Proactive measurement of infliximab trough levels vs. clinical management in inflammatory bowel disease: multicentre study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P425: Rates of tuberculosis infection in Crohn’s Disease patients before and during anti-tumor necrosis factor therapy
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P425: Real-world evidence on effectiveness and safety of vedolizumab therapy for inflammatory bowel disease in Taiwan: Results from the TSIBD registry (VIOLET Study)
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P425: The utility of intestinal ultrasound to inform clinical decision making
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P426 In failure of non-optimised adalimumab (ADA) with therapeutic serum levels, a change in biotherapy class is greater than an intensification of ADA dose in IBD patients
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P426: Association Between vedolizumab therapy outcome and Pre-treatment DUBLIN Score & CRP-Albumin Ratio in Ulcerative Colitis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P426: Health-Related Quality of Life and Work Productivity in patients with moderate-to-severe Inflammatory Bowel Disease in Argentina: Data from the RISE AR study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P426: Lympocytosis in patients with inflammatory bowel disease treated with anti-TNFa agents: is it significant?
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM